Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among US Adults: Updated Recommendations of the Advisory Committee on Immunization Practices-United States, 2022

What is already known about this topic? Currently, the 13-valent pneumococcal conjugate vaccine (PCV) (PCV13) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23) are recommended for U.S. adults. Recommendations vary by age and risk groups. What is added by this report? On October 20, 2021, the Advisory Committee on Immunization Practices recommended 15-valent PCV (PCV15) or 20-valent PCV (PCV20) for PCV-naive adults who are either aged >= 65 years or aged 19-64 years with certain underlying conditions. When PCV15 is used, it should be followed by a dose of PPSV23, typically >= 1 year later. What are the implications for public health practice? Pneumococcal vaccination recommendations were simplified across age and risk group. Eligible adults may receive either PCV15 in series with PPSV23 or PCV20 alone.

Automated summary

This report highlights the revised pneumococcal vaccination recommendations for U.S. adults. For PCV-naive adults aged >= 65 years or aged 19-64 years with certain underlying conditions, the Advisory Committee on Immunization Practices now recommends either 15-valent PCV (PCV15) or 20-valent PCV (PCV20). When PCV15 is used, a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) should be administered at least 1 year later.